Evidence map›Paper›PMID 37884825›Full record

ReviewEndocrine2024

Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry?

Marta Araujo-Castro, Eider Pascual-Corrales, Patricia Martín Rojas, Paola Parra Ramírez

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Marta Araujo-CastroEndocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. marta.araujo@salud.madrid.org.ORCID 0000-0002-0519-0072
Eider Pascual-CorralesEndocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Patricia Martín RojasEndocrinology & Nutrition Department, Hospital Universitario La Paz Madrid, Madrid, Spain.
Paola Parra RamírezEndocrinology & Nutrition Department, Hospital Universitario La Paz Madrid, Madrid, Spain. paprch@gmail.com.ORCID 0000-0002-0310-7095
Hospital Universitario La Paz · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESMadrid Health Service · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo summarize the available data on the prevalence, clinical repercussion, and diagnosis of primary aldosteronism (PA) and to discuss the SPAIN-ALDO registry's findings, which is the largest PA patient registry in Spain.

methodsA comprehensive review of the literature focused on the prevalence, clinical presentation and diagnosis of PA was performed.

resultsPA is the most common cause of secondary arterial hypertension. In addition, PA patients have a higher cardio-metabolic risk than patients with essential arterial hypertension matched by age, sex, and blood pressure levels. However, despite its high prevalence and associated metabolic and cardiovascular complications, PA remains largely under-recognized, with less than 2% of people in at-risk populations ever tested. The diagnostic investigation is a multistep process, including screening, confirmatory testing, and subtype differentiation of unilateral from bilateral PA forms. Data from the SPAIN-ALDO registry have shed light on the cardiometabolic impact of PA and about the limitations in the PA diagnosis of these patients in Spain.

conclusionsThe most common cause of secondary hypertension is PA. One of the most challenging aspects of the diagnosis is the differentiation between unilateral and bilateral PA because adrenal venous sampling is a difficult procedure that should be performed in experienced centers. Data from the SPAIN-ALDO registry have provided important information on the nationwide management of this pathology.

Indexed as

HyperaldosteronismHypertensionAldosteroneBlood PressureHumansReninSpainAldosteroneReninLeft ventricular hypertrophyPlasma aldosterone concentrationplasma renin activityPrimary aldosteronism

Identifiers

PMID37884825
OpenAlexW4387966722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.